We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Invitrogen Licenses Technology for Fluorescent microRNA Labeling Kits

By Labmedica staff writers
Posted on 11 Mar 2008
Using Genisphere Inc.'s (Hatfield, PA, USA) 3DNA dendrimer signal amplification technology, Invitrogen Corp. (Carlsbad, CA, USA) will become the exclusive provider of fluorescent microRNA (miRNA) microarray labeling kits, according to a new license agreement. Genisphere's technology is combined with Invitrogen's Alexa Fluor fluorescent dyes and commercialized in the new NCode rapid miRNA labeling system, which is available from Invitrogen.

Genisphere's 3DNA dendrimer technology is based on highly branched DNA structures serving as scaffolds for multitudes of fluorescent dyes. As a class, dendrimers are complex, branched molecules built from interconnected natural or synthetic monomeric subunits. A 3DNA dendrimer is constructed from DNA monomers, as the name "3DNA” indicates.

Each 3DNA monomer is composed of two DNA strands that share a region of sequence complementarily located in the central portion of each strand. When the two strands anneal to form the monomer the resulting structure has a central double-stranded "waist” bordered by four single-stranded "arms.” This waist plus arms structure comprises the basic 3DNA monomer.

"Our new kit accelerates the discovery of novel miRNA biomarkers by reducing the amount of time scientists must invest to detect miRNAs. In addition, we have increased sensitivity compared to alternative technologies, which can preserve precious samples,” said Peter Welch, director of research and development, gene expression profiling at Invitrogen. "Because miRNAs play a significant role in cancer and in the differentiation of stem cells, discoveries resulting from experiments in those areas could potentially expedite the diagnostics applications of miRNA biomarkers in disease.”


Related Links:
Genisphere
Invitrogen

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control

Latest Industry News

New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
11 Mar 2008  |   Industry

Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada
11 Mar 2008  |   Industry

Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial
11 Mar 2008  |   Industry